A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-07976016 AND PF-06882961 IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity.
The total number of weeks of the study is up to approximately 22 weeks (5.5 months).

Start Date13 Mar 2025

Sponsor / Collaborator

Pfizer Inc.

NCT06541678

/ CompletedPhase 1

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Itraconazole and Cyclosporine on the Single-Dose Pharmacokinetics of Danuglipron in Healthy Adult Participants

The purpose of this study is to see how single dose of cyclosporine and multiple doses of itraconazole affect the level of the study medicine danuglipron in the blood of healthy adult participants. The information from this study may inform how danuglipron will be used in the future with medicines like cyclosporine and itraconazole.

Start Date23 Dec 2024

Sponsor / Collaborator

Pfizer Inc.

NCT06567327

/ CompletedPhase 1

A Two-Part Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Multiple Dose Pharmacokinetics of Danuglipron Following Oral Administration and The Effects of Steady-State Danuglipron on the Pharmacokinetics of Single Oral Dose of Atorvastatin and Rosuvastatin in Otherwise Healthy Adult Participants With Overweight or Obesity

The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese:
* how the study medicine, danuglipron, is taken up into the blood
* if the study medicine, danuglipron, changes how the body processes other study medicines (Atorvastatin and Rosuvastatin)
* about the safety and tolerability of danuglipron
The study will take place in 4 Cohorts (groups). The total number of weeks of the study is about 23 (about 6 months) for Cohort 1 and 22 weeks (about 5.5 months) for Cohort 2, 21 weeks (about 5 months) for Cohort 3 and 20 weeks (about 5 months) for Cohort 4.

Start Date28 Aug 2024

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Danuglipron

100 Translational Medicine associated with Danuglipron

100 Patents (Medical) associated with Danuglipron

Literatures (Medical) associated with Danuglipron

01 Jan 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist danuglipron using UHPLC-QToF-MS/MS

Article

Author: Deshmukh, Vaibhav ; Nandi, Sukhendu ; Jaiswal, Anupam ; Biradar, Rushikesh ; Deshpande, Rashmi

Small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists are emerging as promising therapeutic agents for type 2 diabetes mellitus (T2DM) and obesity. Danuglipron, a novel investigational GLP-1R agonist, has demonstrated notable efficacy in clinical trials. This study aimed to evaluate the in vitro metabolic stability of danuglipron and to identify its metabolites both in vitro and in vivo. Metabolite profiling was conducted using ultra-high-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry (UHPLC-QToF-MS/MS). In vitro studies were performed in human liver microsomes (HLM), rat liver microsomes (RLM), and human S9 (HS9) fractions, while in vivo metabolites were identified from rat plasma, urine, and faeces. Seven novel phase I and phase II metabolites were characterized through high-resolution MS data, employing both data-dependent and data-independent acquisition, alongside in silico prediction tools. Key biotransformations included hydroxylation, O-dealkylation, oxetane ring hydrolysis followed by acetylation and methylation. The in vitro half-life (t₁/₂) of danuglipron was 208 ± 31 min in HLM and 81 ± 16 min in RLM, with corresponding intrinsic clearance (CL_int) values of 7.49 µL/min/mg and 35.57 µL/min/mg, respectively, indicating moderate hepatic metabolism and low clearance in both species. Molecular docking suggested that certain metabolites (M-1, M-2, M-7) may have stronger GLP-1R binding affinity than the parent compound, implying potential bioactivity. This comprehensive analysis offers valuable insights into danuglipron metabolic fate and supports further investigation of its metabolites in the treatment of T2DM and obesity.

01 Sep 2025·DIABETES OBESITY & METABOLISM

Efficacy and safety of danuglipron ( PF ‐06882961) in adults with obesity: A randomized, placebo‐controlled, dose‐ranging phase 2b study

Article

Author: Sherry, Nicole ; Halstead, Patricia ; Saxena, Aditi R. ; Matsuoka, Osamu ; Cobain, Sonia ; Fukushima, Yasushi ; Tsamandouras, Nikolaos ; Bays, Harold E. ; Gorman, Donal N. ; Buckeridge, Clare

Abstract:

Aims:

This randomized, double‐blind, placebo‐controlled Phase 2b study aimed to assess the efficacy, safety, and tolerability of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, in adults with obesity.

Materials and Methods:

Eligible participants (aged 18–75 years; with obesity, without diabetes) were randomized to receive danuglipron or placebo twice daily (BID) for 26 or 32 weeks. Danuglipron was escalated to doses of 40–200 mg BID in 1‐, 2‐, or 4‐week intervals. Assessments included body weight, waist circumference, and safety evaluations.

Results:

Overall, 628 participants were randomized; of 626 receiving study treatment (placebo, n = 90; danuglipron, n = 536), 39.3% completed treatment. Approximately 38% of participants discontinued treatment because of adverse events (AEs) and 22% discontinued for other reasons. The primary endpoint was the change in weight from baseline to the end of treatment; all danuglipron groups demonstrated statistically significant reductions with least squares mean percentage decreases from baseline ranging from −5.0% (90% confidence interval [CI] −6.8%, −3.2%) to −12.9% (90% CI −16.1%, −9.5%) relative to placebo. Danuglipron was considered safe. Consistent with the mechanism, the most frequently reported events were nausea and vomiting, and increased rates of gastrointestinal AEs were generally observed at higher doses. Most events were reported as mild, and no other dose‐related trends were observed in safety endpoints.

Conclusions:

In participants with obesity, danuglipron resulted in statistically significant and clinically meaningful reductions in body weight versus placebo over 26 or 32 weeks. The overall safety profile observed in this study was consistent with expectations for the mechanism, although discontinuation rates due to AEs were higher than anticipated across all treatment groups, including placebo.ClinicalTrials.gov identifier : NCT04707313.

26 Aug 2025·CURRENT MEDICINAL CHEMISTRY

"Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024)

Article

Author: Saliev, Alexandr Yu. ; Ivanov, Roman A. ; Salakhov, Tagir L. ; Tolkacheva, Elena V. ; Balakin, Konstantin V. ; Chernyshov, Vladimir V.

Background::

GLP-1 receptor peptide agonists have revolutionized type 2 di-abetes mellitus and obesity treatment, primarily through injection-based therapies. Small-molecule GLP-1 receptor agonists allow oral administration, but none are clini-cally established. Pfizer's danuglipron and lotiglipron, presented in 2018-2019, were "first-in-class" drug candidates, becoming prototypes for "next-in-class" drug develop-ment.

Objective::

This review summarizes "next-in-class" GLP-1 receptor agonists developed, identifying different relationships between the molecular structure and functional activi-ty of agonists.

Methods::

Patents containing danuglipron- and lotiglipron-like agonists from January 2021 to July 2024 were browsed in databases, such as Espacenet and Google Patents, using specified keywords. Over 5,000 compounds from 67 patent publications were an-alyzed.

Results::

Our analysis identified some key general SAR trends. The presence of a car-boxyl group leads to highly active agonists, but replacing it with bioisosteric analogs may improve the ADME profile of the target compounds. The introduction of specific privileged fragments, as well as the replacement of 1H-benzo[d]imidazole nucleus or (S)-oxetan-2-ylmethyl substituent in the prototype structure with bioisosteric heterocy-cles, may be viable approaches. The replacement of 1,4-disubstituted piperidine linked with its (S)-2-methyl-substituted homologue or O, N-disubstituted piperidin-4-ol may also result in highly potent agonists. Additionally, the classic 2,4-EWG-disubstituted benzyl alcohol residue allows significant variability.

Conclusion::

Despite the limited clinical success of danuglipron and lotiglipron, as well as the inherent problems associated with the complex nature of GLP-1R signaling, the current state of research and the abundance of novel, promising chemotypes of highly potent compounds suggest that approved GLP-1R agonists may emerge in the coming years.

News (Medical) associated with Danuglipron

15 Nov 2025

·endpoints.news

Inside the Metsera bidding war; PD-(L)1xVEGF bispecific race heats up; Pazdur tapped as next CDER head; and more

Welcome back to Endpoints Weekly. It’s going to be a chilly weekend here in Boston, with low temperatures dipping into the 30s — the perfect weather for a warm cup of tea while recapping another busy week in biopharma. If you haven’t already, be sure to read the Endpoints team’s exclusive on how Pfizer closed its deal with Metsera. We also have a feature from Max Gelman on how competition is stacking up in the PD-(L)1xVEGF space, details on Richard Pazdur’s appointment to CDER, some positive results for Roche’s BTK inhibitor, and the story behind a new VC firm hunting for the next big advances in obesity treatment. We’ll be back on Monday. Until then, stay warm! — Nicole DeFeudis 💇‍♂️Pfizer completed its up to $10 billion acquisition of the obesity biotech Metsera this week, ending a high-stakes bidding war between Pfizer and Novo Nordisk. Last week, we reported that Metsera had accepted Pfizer’s offer after the FTC warned the biotech that Novo’s bid was risky under US antitrust law. But you can see exactly how the final deal unfolded in this exclusive by Endpoints’ Elizabeth Cairns, Kyle LaHucik and Drew Armstrong — including how Metsera’s co-founder Paul Berns was in the middle of a haircut when he was alerted that Novo was submitting its surprise offer. The deal gives Pfizer a fresh chance in obesity after the company dropped its obesity pill danuglipron in April. Novo fought hard for Metsera, as it looks to maintain a leading stake in the obesity market. But even though Pfizer won the battle, all eyes will be on how the experimental drugs it acquired perform in trials. Stay tuned. 🏎️ Drugmakers in the PD-(L)1xVEGF space are revving their engines, Endpoints’ Max Gelman reported this week. While much of the focus has been on Summit Therapeutics and its lead drug ivonescimab, two other rival teams have recently detailed their clinical development plans. Check out Max’s in-depth look at the competition here. One of the challengers is Pfizer and 3SBio, which inked a licensing deal for a PD-1xVEGF bispecific called SSGJ-707, or PF’4404, earlier this year. Pfizer said on Monday that among other trials, it has plans for a Phase 3 study in first-line metastatic colorectal cancer and a Phase 3 non-small cell lung cancer study evaluating both squamous and non-squamous tumors. Bristol Myers Squibb and BioNTech are also in the running. They teamed up this year to advance a PD-L1xVEGF program that BioNTech got in its Biotheus acquisition. Bristol Myers outlined plans for five mid- and late-stage studies during an earnings call last month, and BioNTech said this week that it’s also looking at studies in pancreatic cancer, ovarian cancer and glioblastoma. Both companies intend to look at combinations within their respective pipelines, Max reported. Despite all the momentum, the race could take a while to play out as Summit plans to launch more studies and we wait for key data from Pfizer and BMS. Longtime cancer chief Richard Pazdur was appointed to lead the Center for Drug Evaluation and Research, just over a week after former director George Tidmarsh’s sudden resignation. Pazdur has 26 years of experience at the agency and is the founding director of the FDA’s Oncology Center of Excellence. During his time at the FDA, he has been focused on speeding up the development of new cancer therapies. Pazdur vs. Prasad: Current CBER Director Vinay Prasad previously criticized Pazdur in social media posts before Prasad joined the FDA. Endpoints’ Zachary Brennan analyzed the complex dynamic and the events that led to Pazdur’s appointment here. 💵Two former executives of Lilly’s diabetes unit have launched a venture capital firm called 501 Ventures, and they’re looking for the next approaches to obesity treatment. The firm will fund science for next-generation metabolic health medicines. Its founders, Enrique Conterno and Meg Powell, wouldn’t disclose the amount of capital they’re working with so far. But Powell said they’ll court pharma companies to help support the fund. Kyle LaHucik reported the details from this year’s ObesityWeek conference in Atlanta. Read more here . Roche reported positive results from two separate Phase 3 trials that tested fenebrutinib in relapsing multiple sclerosis and primary progressive multiple sclerosis. Roche hasn’t shared the detailed results, but CMO Levi Garraway described the wins as “unprecedented.” Roche said it will wait for data from a second Phase 3 RMS trial before finalizing regulatory filing plans.

Phase 3Executive ChangeAcquisitionLicense out/in

03 Nov 2025

·www.pharmaceutical-technology.com

Pfizer hits Novo Nordisk and Metsera with lawsuit amid bidding war

Pfizer has filed a lawsuit against rival big pharma company, Novo Nordisk, and obesity biotech, Metsera, following an M&A bidding war between Novo Nordisk and Pfizer. Image credit: Indypendenz via Shutterstock.com. Pfizer has followed through on its threats, filing a lawsuit against both Metsera and Novo Nordisk during a M&A bidding war for the obesity-focused biotech. This follows Novo Nordisk’s last-minute interception of Pfizer’s September 2025 acquisition deal for the New York-based biotech, which could see Pfizer pay up to $7.3bn for the rights to Metsera. Through its counter-offer , Novo Nordisk trumped this value, offering Metsera up to $9bn, which the biotech considered a “superior company proposal”. The lawsuit, filed in the Delaware Court of Chancery, alleges that Novo Nordisk and Metsera breached the contractual merger agreement, claiming “breach of contract, breach of fiduciary duty, and tortious interference”. Pfizer made additional claims against Novo Nordisk in its lawsuit announcement, alleging that the Danish pharma’s acquisition offer of Metsera is an “illegal attempt by a company with a dominant market position to suppress competition” in the obesity field, as Novo Nordisk currently holds a dominant market position in this segment. Pfizer refuted Metsera’s claims that Novo Nordisk’s proposal was superior, noting that it “cannot qualify as superior” relative to its deal with Metsera under the merger agreement. In Pfizer’s eyes, this is because Novo Nordisk’s transaction is unlikely to be completed due to the regulatory risk associated with it. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence In a statement released on 31 October, Metsera noted that it “disagrees with the allegations in Pfizer’s complaint”, adding that the company will address them in court. Metsera’s future up in the air Despite its souring sentiments toward the obesity biotech, Pfizer plans to soldier on with the acquisition, which could be ready to complete following a Metsera stockholder meeting on 13 November. In an attempt to block any further discourse on this matter, Pfizer has also filed a motion with the Court of Chancery to request a temporary restraining order on Metsera to block the biotech from terminating the merger agreement, which Pfizer noted would give it “time to be heard on this important matter”. Despite Novo Nordisk’s attempt to intercept Pfizer’s deal with Metsera, it appears that the latter may prevail, as the US Federal Trade Commission granted early termination of the waiting period to the New York pharma’s pending acquisition. Obesity market spikes big pharma interest This back-and-forth comes at a time when Pfizer is keen to make its name in the metabolic health sector, which GlobalData forecasts will be worth $206.5bn in 2031 – up from $12.3bn in 2021. GlobalData is the parent company of Pharmaceutical Technology . Currently, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are consistently delivering high sales performance, with Eli Lilly’s star type 2 diabetes and obesity assets, Mounjaro and Zepbound (tirzepatide), bringing in $6.5bn and $3.6bn in Q3 alone – surpassing analyst expectations and raising the company’s projected revenue ceiling for this financial year. Novo Nordisk and Eli Lilly have been the two key players in this segment, fighting for market share with their best-selling injectable GLP-1RAs, Wegovy (semaglutide) and Zepbound. However, Pfizer has been looking to jump on the obesity bandwagon, having developed its own assets to compete with both Lilly and Novo Nordisk’s marketed therapies. Despite its efforts to develop an oral GLP-1RA, Pfizer had to terminate the development programme for its obesity pill , danuglipron, after the medication caused a drug-induced liver injury in a Phase IIa trial. If Pfizer’s acquisition of Metsera is completed, the big pharma will claim Metsera’s range of obesity assets, including monthly GLP-1RA, MET-097i, which recently posted weight loss of 14.1% in a Phase IIb trial. Alongside its next-generation injectable portfolio, Metsera could offer Pfizer another chance at commercialising an oral obesity drug, as the company’s MET-224o pill is currently in Phase I trials. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

AcquisitionPhase 1Phase 2Clinical Result

01 Nov 2025

·endpoints.news

Novo makes a play for Metsera; This week’s other big deal; Earnings in full swing; and more

Welcome back to Endpoints Weekly, and welcome to November. This week kicked off with quarterly earnings results from a handful of companies, including Eli Lilly, Merck, Novartis and Bristol Myers Squibb. Then on Thursday, Novo Nordisk made waves when it announced that it submitted an unsolicited bid for the obesity biotech Metsera, a month after Pfizer disclosed its plans to acquire it. The Endpoints team is following the saga closely, so stay tuned for more details. Novartis also made headlines this week for its $12 billion offer to buy out a neuromuscular drug developer. And Ryan Cross has an exclusive on a low-profile biotech targeting one of the immune system’s natural defenses to potentially treat autoimmune disease. We’ll have reporters covering earnings results next week from Pfizer, Novo Nordisk, Moderna and more. Until then, have a great weekend! — Nicole DeFeudis 🤼 Novo Nordisk shocked the industry this week by announcing it made an unsolicited bid for obesity biotech Metsera for $6.5 billion upfront. Pfizer, which had announced its intent to buy out Metsera last month for $4.9 billion upfront, almost immediately came out swinging, saying Novo’s bid was “in violation” of antitrust law. This is going to be one of those stories where things can change quickly — evidenced by Pfizer suing Metsera and Novo late Friday — and we’ll have you covered from every angle. From Novo’s side, the bid comes ahead of new CEO Maziar Mike Doustdar’s first earnings call next week. The Danish drugmaker has been in the midst of “turning the [bleeping] tanker,” as Logan Roy from HBO’s “Succession” would say. As Elizabeth Cairns and Kyle LaHucik wrote earlier this week , Novo has faced significant pressure from GLP-1 competitor Eli Lilly, laying off thousands of staffers and cutting back on pipeline projects. But with this week’s Metsera offer, Doustdar appears to be chasing the deals his predecessors wouldn’t , Liz writes. For Pfizer, analysts say CEO Albert Bourla could be leveraging his relationship with President Donald Trump, with a company statement emphasizing the anticompetitive nature of the bid by letting Novo Nordisk take over “an emerging American challenger.” The stakes for Pfizer are high, as it dropped an oral GLP-1 called danuglipron when it caused intolerable liver side effects in one patient earlier this year. The back-and-forth will also pose a test to Trump’s FTC , Jared Whitlock writes. Metsera, meanwhile, appears content to let Novo and Pfizer duke it out to try to drive up the price. The biotech also put out a statement this week that said it views Novo’s offer as a “superior proposal,” which would legally give Pfizer until Nov. 4 to submit a counterbid. But Pfizer noted in its own statement that the Novo offer is “illusory and cannot qualify as a superior proposal” and subsequently sued to enforce the transaction. What’s next in this unfolding saga? Kyle LaHucik takes a look at six burning questions going forward, while Elizabeth Cairns asks what Metsera might bring to Novo . We also broke down the news on an emergency session of Post-Hoc Live , where Kyle and Drew Armstrong chatted with analyst Evan Seigerman. Pfizer is expected to report its third-quarter earnings on Nov. 4. 💰 Novartis has offered about $12 billion to acquire Avidity Biosciences, a neuromuscular drugmaker that’s months away from submitting its lead candidate to the FDA. It’s the second-largest deal announcement of the year. But Novartis CEO Vas Narasimhan said during the company’s third-quarter earnings call on Thursday that the deal could have been “twice as big” if they had waited for a Phase 3 readout, which is expected to come next year. “In our view, the phase-appropriate risk was reasonable given the data that we’ve seen,” Narasimhan said. Novartis is getting three candidates in late-stage testing for Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), and myotonic dystrophy type 1 (DM1). Meanwhile, Avidity plans to spin out its early-stage R&D work in precision cardiology into a separate company that will maintain partnerships with Bristol Myers Squibb and Eli Lilly. The spinout will be led by Avidity’s current chief program officer Kathleen Gallagher. The new company will be publicly traded and get $270 million in cash to support its pipeline. 📊 Biopharma companies are diving headfirst into earnings season, with several big names reporting third-quarter results this week. Here are some of the highlights: 🧬 A new startup called Neutrolis is taking a look at how one of the strangest ways the immune system defends our bodies from invaders can be leveraged to create new drugs. Ryan Cross took an in-depth look at this process that involves neutrophil extracellular traps, or NETs, as Neutrolis has put together more than $50 million in seed and Series A financing. Along with the funding, Neutrolis put out data this week from a Phase 1 study, showing the drug can quickly chop up NETs and potentially help those with autoimmune disorders get a “reset.” Most promising was the data from one patient. Within six hours of infusing him with the treatment, more than 80% of the rashes that covered him from head to toe were cleared, arthritis in multiple joints was resolved, and inflammation in his eyes was reduced. ✅ BridgeBio touted multiple late-stage wins this week, including in a rare disease called limb-girdle muscular dystrophy type 2I/R9. At the study’s interim analysis, BridgeBio’s drug BBP-418 showed a positive result on a specific protein that was originally expected to be used as a surrogate endpoint to seek accelerated approval. But because BBP-418 also hit statistical significance on multiple endpoints, BridgeBio will now ask the FDA whether there is a path to full approval. In another study, BridgeBio’s oral drug encaleret hit the primary endpoint for a genetic thyroid disorder called autosomal dominant hypocalcemia type 1, or ADH1. Based on the data, the biotech said it plans to file for full FDA approval in the first half of next year. Read more from Max Gelman here .

AcquisitionClinical ResultPhase 1

100 Deals associated with Danuglipron

External Link

KEGG	Wiki	ATC	Drug Bank
D11910	-	-	DB16043

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	Phase 2	United States	Pfizer Inc.	06 Jan 2021
Diabetes Mellitus, Type 2	Phase 2	United States	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Bulgaria	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Canada	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Hungary	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Poland	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Slovakia	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	South Korea	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Taiwan Province	Pfizer Inc.	15 Oct 2019
Liver Injury	Phase 1	United States	Pfizer Inc.	30 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04889157 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	20	Placebo	qpsdikisau = akbrhbekew qvbrkahmvd (icgqthfrgp, ptiuyqphgl - oojrlowbwq) View more	-	01 Oct 2024
NCT04616027 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	42	PF-06882961 (Healthy and Normal Renal Function)	zhtvfmozze(bwclaxqilj) = zwoivebdah zedigjtwxt (kzdxehypss, 28) View more	-	10 May 2024
				PF-06882961 (T2DM Normal Renal Function)	zhtvfmozze(bwclaxqilj) = tkfthgaouc zedigjtwxt (kzdxehypss, 58) View more
NCT04604496 (CTgov)	Phase 1	Liver Injury	24	PF-06882961 (Without Hepatic Impairment)	htwmybfdse(ldssaydfbq) = xzdeckhvin brufbopmda (sznbbtjcle, 50) View more	-	21 Mar 2024
				PF-06882961 (Mild Hepatic Impairment)	htwmybfdse(ldssaydfbq) = cjpdjndivq brufbopmda (sznbbtjcle, 33) View more
NCT04707313 (Corporate Publications) Manual	Phase 2	Obesity	-	Danuglipron	jalpljsrqx(rgtqdtkmga) = mntrrmynaq nhmkpevgae (nowfmnkuys ) View more	Negative	01 Dec 2023
				Placebo	jalpljsrqx(rgtqdtkmga) = aiihnayadv nhmkpevgae (nowfmnkuys ) View more
NCT04621227 (CTgov)	Phase 1	Obesity	16	Rosuvastatin (Rosuvastatin 10mg (Period 1))	rvpelyxsmm(nmcsghqlia) = afvgfotrhq gemjptgboz (klyrujzpli, 43) View more	-	01 Dec 2023
				Rosuvastatin+PF-06882961 (PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4))	rvpelyxsmm(nmcsghqlia) = pzsuwkbqtq gemjptgboz (klyrujzpli, 50) View more
NCT04617275 (Pubmed)	Phase 2	Diabetes Mellitus, Type 2	151	Placebo	lapehsmtzi(meceluyqnc) = kydaiemjlh hyreomtysu (wyfzegecyu ) View more	-	13 Jun 2023
				Danuglipron low starting dose (5-mg)	lapehsmtzi(meceluyqnc) = dgwtxdxmeo hyreomtysu (wyfzegecyu ) View more
NCT03985293 (Literature) Manual	Phase 2	Diabetes Mellitus, Type 2	411	Danuglipron 2.5 mg	xagzkulrwx(fojrwkbfxw) = wvvrqsgvtf dtadgmarpc (oaghistpmi, -0.70 to to 0.28) View more	Positive	22 May 2023
				Danuglipron 10 mg	xagzkulrwx(fojrwkbfxw) = gdvqmezxzb dtadgmarpc (oaghistpmi, -1.11 to to 0.72) View more
NCT03985293 (Pubmed)	Phase 2	Diabetes Mellitus, Type 2	411	Danuglipron 2.5 mg	udwjjlkunt(ajbbkeylay) = dqydqbjckn lzftkpfmmt (dhlkbndcym, -1.47 to -0.86) View more	Positive	01 May 2023
				Danuglipron 80 mg	ogcmcebyau(yplifpplmr) = yqimkirpbr jzesrlplai (vrbujdvqwi, -3.01 to -1.07)
NCT04617275 (CTgov)	Phase 2	Diabetes Mellitus, Type 2 \| Obesity	151	Placebo (Placebo (T2DM))	muczkkigfd = adiszuseiu urvikihula (aaaqzonjsa, aehntjrieb - tjsweokpqa) View more	-	08 Dec 2022
				PF-06882961 (PF-06882961 80 mg BID Low, Slow (T2DM))	muczkkigfd = uetponthzj urvikihula (aaaqzonjsa, mmnjmkdchk - rjurtfqubu) View more
NCT04552470 (Pubmed) Manual	Phase 1	Diabetes Mellitus, Type 2	37	danuglipron	nvgcewhgru(zzykfzcuez) = Most treatment-emergent adverse events were of mild or moderate intensity. sjzchgejxe (trkfzqgcoy )	Positive	26 Nov 2022
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis